多发小非进展期腺瘤患者异时性进展期肿瘤风险研究
该研究分析了5482例首次结肠镜筛查发现腺瘤并接受随访结肠镜的患者,按基线腺瘤特征分为四组。中位随访38个月,异时性进展期肿瘤总体发生率为5.6%。与低风险组1相比,≥3个非进展期小腺瘤(1-5mm)组调整HR为1.71(95%CI 0.99-2.94),风险呈边缘性升高。
要点
- ≥3个非进展期小腺瘤(1-5mm)患者异时性进展期肿瘤风险较1-2个非进展期腺瘤患者呈边缘性升高(调整HR 1.71,95%CI 0.99-2.94)。
- ≥3个非进展期小腺瘤(6-9mm)和进展期腺瘤患者异时性进展期肿瘤风险显著升高(调整HR分别为2.76和5.23)。
- 中位随访38个月,异时性进展期肿瘤总发生率为5.6%。
核心结论
- 与低风险腺瘤患者相比,≥3个非进展期小腺瘤(1-5mm)患者异时性进展期肿瘤风险呈边缘性升高。
研究设计与样本
- 研究分析了5482例首次结肠镜筛查诊断一个或多个腺瘤并接受随访结肠镜的患者,按基线腺瘤特征分为四组:组1为1-2个非进展期腺瘤,组2为≥3个非进展期小(1-5mm)腺瘤,组3为≥3个非进展期小(6-9mm)腺瘤,组4为进展期腺瘤。
主要发现
- 中位随访38个月,随访结肠镜检出的异时性进展期肿瘤发生率为5.6%。
- 异时性进展期肿瘤发生率在组1为3.9%,组2为5.9%,组3为10.6%,组4为22.1%。
- 与低风险组1相比,组2、组3、组4发生异时性进展期肿瘤的调整HR(95%CI)分别为1.71(0.99-2.94)、2.76(1.72-4.44)、5.23(3.57-7.68)。
- 与组4相比,组1、组2、组3的调整HR(95%CI)分别为0.19(0.13-0.28)、0.32(0.18-0.59)、0.52(0.31-0.89)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Individuals with advanced adenomas or three or more adenomas have a higher risk of metachronous advanced neoplasia (AN) and are recommended to undergo surveillance colonoscopy at shorter intervals. However, it is questionable whether patients with multiple (three or more) non-advanced diminutive adenomas should be considered as high-risk. METHODS: We analyzed 5482 patients diagnosed with one or more adenomas during their first colonoscopy screening and who underwent a follow-up colonoscopy. Patients were categorized into four groups based on adenoma characteristics at baseline: Group 1, 1-2 non-advanced adenomas; Group 2, ≥3 non-advanced, diminutive (1 to 5 mm) adenomas; Group 3, ≥3 non-advanced, small (6-9 mm) adenomas; and Group 4, advanced adenomas. RESULTS: During a median follow-up of 38 months, the incidence of metachronous AN at surveillance colonoscopy was 5.6%. The incidence of AN was 3.9% in group 1, 5.9% in group 2, 10.6% in group 3, and 22.1% in group 4. The adjusted hazard ratios (HRs) [95% confidence intervals (CIs)] for metachronous AN between group 2, group 3, and group 4, and low risk group 1 were 1.71 (0.99-2.94), 2.76 (1.72-4.44), and 5.23 (3.57-7.68), respectively. Compared with group 4, the adjusted HRs (95% CIs) for group 1, group 2, and group 3 were 0.19 (0.13-0.28), 0.32 (0.18-0.59), and 0.52 (0.31-0.89), respectively. CONCLUSIONS: We found that patients with three or more non-advanced diminutive adenomas had a borderline increased risk of metachronous AN compared with patients with low risk adenomas.
引用
- Kim JY, Kim TJ, Baek SY, et al. Risk of Metachronous Advanced Neoplasia in Patients With Multiple Diminutive Adenomas. Am J Gastroenterol. 2018. PMID: 30072776. doi:10.1038/s41395-018-0210-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。